Skip to main content
Clinical Trials/KCT0009443
KCT0009443
Completed
未知

Clinical trial to evaluate the safety and efficacy for improvement trapezius hypertrophy of botulax® injection.

Asan Medical Center0 sites20 target enrollmentTBD

Overview

Phase
未知
Intervention
Not specified
Conditions
Factors influencing health status and contact with health services
Sponsor
Asan Medical Center
Enrollment
20
Status
Completed
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
June 19, 2023
Last Updated
last year
Study Type
Interventional Study
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • 1\) A person between the ages of 20 and 60 who want contour correction of the gastrocnemius muscle
  • 2\) A person who can follow the clinical trial procedure well and abide by the visit schedule
  • 3\) Those who voluntarily signed the consent form

Exclusion Criteria

  • 1\) Patients with diseases that can affect neuromuscular function, such as myasthenia gravis, Eaton\-Lamberton syndrome, amyotrophic lateral sclerosis, and motor neuropathy
  • 2\) Aminoglycoside antibiotics, curare\-like agents, or drugs that inhibit neuromuscular function (muscle relaxants such as tubocurarine, dancrolen sodium, and baclofen, anticholinergics, and benzodiazepines) antibiotics, benzamide, tetracycline, lincomycin antibiotics, etc.)
  • 3\) Patients with a history of recent alcoholism or drug misuse
  • 4\) Patients with skin abnormalities such as infections, skin diseases, or scars at the injection site
  • 5\) If you have had other procedures that may affect gastrocnemius treatment within 6 months prior to baseline
  • 6\) Those who have received botulinum toxin preparations within 6 months before baseline
  • 7\) Patients with a history of facial nerve palsy or ptosis
  • 8\) Those taking aspirin, NSAIDs or anticoagulants
  • 9\) A woman who is pregnant, lactating, or of childbearing potential who does not agree to contraception by a medically accepted method for up to 8 weeks after drug administration
  • 10\) A person who has rapidly lost weight

Outcomes

Primary Outcomes

Not specified

Similar Trials